THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS-Reference-Cited by-同舟云学术

THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS

Published:2019-06 Issue: Volume:37 Page:89-90
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematol Oncol

Author:

Advani R.¹,Bartlett N.L.²,Smith S.M.³,Roschewski M.⁴,Popplewell L.⁵,Flinn I.⁶,Collins G.⁷,Ghosh N.⁸,LaCasce A.⁹,Asch A.¹⁰,Kline J.³,Kesevan M.⁷,Tran T.¹,Lynn J.¹¹,Huang J.¹¹,Agoram B.¹¹,Volkmer J.¹¹,Takimoto C.H.¹¹,Chao M.P.¹¹,Mehta A.¹²

Affiliation:

1. Medicine; Stanford University; Stanford United States

2. Medicine; Washington University St. Louis; St, Louis United States

3. Medicine; University of Chicago; Chicago United States

4. Lymphoid Malignancies Branch; National Cancer Institute; Bethesda United States

5. Hematology/Oncology; City of Hope; Duarte United States

6. Medicine; Sarah Cannon Research Institute; Nashville United States

7. Clinical Haematology; Oxford University; Oxford United Kingdom

8. Medicine; Atrium Health; Charlotte United States

9. Medicine; Dana Farber Cancer Institute; Boston United States

10. Hematology/Oncology; University of Oklahoma; Oklahoma City United States

11. Clinical Development; Forty Seven, Inc.; Menlo Park United States

12. Medicine; University of Alabama Birmingham; Birmingham United States

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hon.57_2629/fullpdf

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single Agent and Rational Combination Experiences with Anti‐ CD 47 Targeted Drugs;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

2. Moving beyond chemotherapy in the management of follicular lymphoma;Canadian Hematology Today;2022-11-01

3. Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies;Leukemia & Lymphoma;2022-06-15

4. Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era;Frontiers in Immunology;2022-06-01

5. Prospects in the management of patients with follicular lymphoma beyond first-line therapy;Haematologica;2022-01-01